Engineers Gate Manager LP Novavax Inc Transaction History

Engineers Gate Manager LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.8 - $7.67 $178,161 - $284,687	37,117 New	37,117 $178,000
Q2 2023 Aug 14, 2023	BUY	$6.67 - $9.52 $162,861 - $232,449	24,417 Added 227.96%	35,128 $261,000
Q1 2023 May 15, 2023	SELL	$5.76 - $12.48 $137,687 - $298,321	-23,904 Reduced 69.06%	10,711 $74,000
Q4 2022 Feb 14, 2023	BUY	$8.86 - $25.04 $306,688 - $866,759	34,615 New	34,615 $355,000
Q2 2022 Aug 15, 2022	BUY	$36.28 - $75.29 $438,734 - $910,481	12,093 New	12,093 $622,000
Q1 2022 May 16, 2022	SELL	$69.73 - $142.9 $873,995 - $1.79 Million	-12,534 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $1.69 Million - $2.73 Million	12,534 New	12,534 $1.79 Million
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $238,429 - $362,847	-1,341 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$121.0 - $257.67 $1.31 Million - $2.79 Million	-10,840 Reduced 88.99%	1,341 $285,000
Q1 2021 May 17, 2021	BUY	$112.98 - $319.93 $1.38 Million - $3.9 Million	12,181 New	12,181 $2.21 Million

284

83.2M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $1.01B
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.